Volume | 498,150 |
|
|||||
News | - | ||||||
Day High | 1.05 | Low High |
|||||
Day Low | 0.9333 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Unicycive Therapeutics Inc | UNCY | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.04 | 0.9333 | 1.05 | 0.97 | 1.04 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
859 | 498,150 | $ 0.9785923 | $ 487,486 | - | 0.47 - 1.8227 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:30:58 | 93 | $ 0.97 | USD |
Unicycive Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
33.71M | 34.75M | - | 675k | -31.41M | -0.90 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Unicycive Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical UNCY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.15 | 1.1999 | 0.9333 | 1.09 | 401,121 | -0.18 | -15.65% |
1 Month | 1.46 | 1.60 | 0.9333 | 1.25 | 399,901 | -0.49 | -33.56% |
3 Months | 0.95 | 1.818 | 0.91 | 1.37 | 390,263 | 0.02 | 2.11% |
6 Months | 0.7696 | 1.818 | 0.47 | 1.17 | 272,891 | 0.2004 | 26.04% |
1 Year | 1.55 | 1.8227 | 0.47 | 1.20 | 198,615 | -0.58 | -37.42% |
3 Years | 8.55 | 8.73 | 0.4004 | 1.96 | 738,101 | -7.58 | -88.65% |
5 Years | 8.55 | 8.73 | 0.4004 | 1.96 | 738,101 | -7.58 | -88.65% |
Unicycive Therapeutics Description
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. |